Table 3 Melanoma systemic treatments and immune-related adverse events (IRAE)
ICI treated (n = 289) | Non-ICI treated (n = 357) | p-value | |
|---|---|---|---|
Pembrolizumab | 41.5% (120) | ||
Nivolumab | 63.0% (182) | ||
Combination Ipilimumab/Nivolumab | 25.6% (74) | ||
Ipilimumab or Nivolumab (blinded) | 1.4% (4) | ||
Other | 1.0% (3) | ||
Any IRAE | 63.7% (184) | ||
Cutaneous | 26.0% (75) | ||
Thyroiditis | 11.4% (33) | ||
Hypophysitis/Hypopituitarism | 5.5% (16) | ||
Adrenal insufficiency/adrenalitis | 3.1% (9) | ||
Enterocolitis | 12.5% (36) | ||
Hepatitis | 9.7% (28) | ||
Pneumonitis | 3.5% (10) | ||
Arthritis | 12.8% (37) | ||
Myocarditis | 0.7% (2) | ||
Any corticosteroid use after ICI | 46.4% (132) | ||
Chronic corticosteroid use (> 30 days) after ICI | 37.8% (107) | ||
TNF-alpha inhibitor use after ICI | 5.5% (16) | ||
Any BRAF ± MEK inhibitor use | 12.5% (36) | 10% (36) | 0.33 |
BRAF ± MEK inhibitor use before baseline | 8.0% (23) | 0.0% (0) | < 0.01 |
BRAF ± MEK inhibitor use after baseline | 4.5% (13) | 12.5% (36) | < 0.01 |